Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB - LARVOL DELTA

Real-World Safety and Efficacy of Romosozumab in Severe Postmenopausal Osteoporosis: A Single-Centre Experience (ACR Convergence 2026) - "In this cohort, Romosozumab had significant improvements in spinal BMD and withlessor but still significant gains at the hip. The therapy was well tolerated, with noobserved cardiovascular events in a carefully selected population.Longer follow-up is required to determine the impact on fracture reduction.Sequential antiresorptive therapy was implemented in all patients in line with currentclinical practice."

Clinical • Real-world • Real-world evidence • Cardiovascular • Musculoskeletal Diseases • Musculoskeletal Pain • Myocardial Infarction • Orthopedics • Osteoporosis • Rheumatology

Effect of Romosozumab on Bone Metabolism, Lipid Profile, and Laboratory Parameters in Real-World Clinical Practice. (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Orthopedics • Osteoporosis • Rheumatology

Global Cardiovascular Safety of Romosozumab in Patients With Rheumatoid Arthritis and Osteoporosis: A Propensity-Matched TriNetX Cohort Study (ACR Convergence 2026) - No abstract available

Clinical • Cardiovascular • Immunology • Inflammatory Arthritis • Osteoporosis • Rheumatoid Arthritis • Rheumatology

Comparative Effectiveness of Sequential Romosozumab-Denosumab vs. Denosumab Alone on Fracture Risk: A Target Trial Emulation Study (ACR Convergence 2026) - No abstract available

HEOR • Musculoskeletal Diseases • Orthopedics

Real-World Romosozumab Utilization Patterns Among Medicare Beneficiaries: A Multistate Analysis (ACR Convergence 2026) - No abstract available

Clinical • Medicare • Real-world • Real-world evidence • Reimbursement • US reimbursement • Orthopedics • Osteoporosis • Rheumatology

Cardiovascular Outcomes with Romosozumab Versus Alendronate in Osteoporosis: A Real-World Propensity-Matched Cohort Study (ACR Convergence 2026) - No abstract available

Clinical • Real-world • Real-world evidence • Cardiovascular • Osteoporosis • Rheumatology

Bayesian Borrowing for Fracture Risk Factors in Female Romosozumab New Users Across Racial and Ethnic Subgroups (ACR Convergence 2026) - No abstract available

Clinical • Musculoskeletal Diseases • Orthopedics

A Pilot Study of Romosozumab in Postmenopausal Women with Myeloma-Related Bone Disease and Osteoporosis (IMS 2026) - "During romo therapy, 4 were on maintenance therapy, 5 on daratumumab-based regimens with 2 proceeding to CART, and 1 on observation...All pts had prior zoledronic acid (ZA) with median time from last dose of ZA to romo start of 22 (range 4-58) mos... In our study, romo was well-tolerated and resulted in significant early increases in bone formation markers (P1NP, osteocalcin, BAP) compared to baseline. Our findings suggest that romo has positive anabolic effects in MM pts without negatively impacting anti-MM therapy."

Clinical • Hematological Malignancies • Multiple Myeloma • Orthopedics • Osteoporosis • Rheumatology

Pharmacological therapies for the prevention of fractures in men. (PubMed, Cochrane Database Syst Rev) - "We are very uncertain about the effects of bisphosphonates compared to placebo on the incidence of hip fractures, symptomatic vertebral fractures, or other (non-hip non-vertebral) fractures in men at up to two years of use. Bisphosphonates probably do not increase the risk of adverse events or serious adverse events, and we are very uncertain if they result in more withdrawals due to adverse events. We downgraded the certainty of evidence for indirectness, imprecision (low event rate), and serious risk of bias in selection of the reported result, as it was unclear if all studies fully reported every fracture. We found similar results for PTH or PTHrP analogues, denosumab, or romosozumab versus placebo. Larger, longer placebo-controlled studies are needed to determine whether pharmacological therapies are beneficial for reducing fractures in men."

Clinical • Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Case Report: Reopening the anabolic window - romosozumab added to ongoing denosumab for severe osteoporosis in two kidney transplant recipients. (PubMed, Front Endocrinol (Lausanne)) - "Adding romosozumab to ongoing denosumab thus reopened the anabolic window and improved lumbar-spine bone mineral density without compromising mineral metabolism or graft function. This combination may represent a reasonable option for carefully selected transplant recipients who continue to lose bone or to fracture despite antiresorptive therapy, pending confirmation in controlled studies."

Journal • Chronic Kidney Disease • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Osteoporosis • Renal Disease • Rheumatology • Transplantation

Cardiovascular Safety Signals of Osteoporosis Therapies: A FAERS Pharmacovigilance Study. (PubMed, Mediterr J Rheumatol) - "We conducted a retrospective pharmacovigilance analysis of FAERS reports between January 2019 and December 2024, identifying all reports involving alendronate, risedronate, zoledronic acid, denosumab, teriparatide, abaloparatide, or romosozumab. Romosozumab and zoledronic acid demonstrated prominent cardiovascular disproportionality signals in FAERS, whereas denosumab, abaloparatide, and teriparatide showed more favorable reporting profiles. These findings should not discourage osteoporosis treatment but underscore the importance of individualised cardiovascular risk assessment and the need for further prospective evaluation to inform safe therapy selection."

Adverse events • Journal • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction • Osteoporosis • Rheumatology

Osteoporosis treatment patterns and bone mineral density response in kidney transplant recipients: A single-center retrospective study (TTS 2026) - "Treatment groups included bisphosphonates (BP; alendronate, n=191), denosumab (n=261), and romosozumab (n=46), with some patients receiving more than one agent. In this cohort of kidney transplant recipients, osteoporosis treatment patterns shifted substantially over the past decade from bisphosphonates toward denosumab and romosozumab. All therapies were associated with improvements in bone mineral density, although the magnitude and anatomical distribution of response differed among agents. These findings reflect recent shifts in clinical practice and support individualized osteoporosis management after kidney transplantation."

Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology • Transplantation

Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (clinicaltrials.gov) - P2 | N=36 | Completed | Sponsor: VA Office of Research and Development | Active, not recruiting ➔ Completed | Trial completion date: Mar 2027 ➔ Aug 2026

Trial completion • Trial completion date • CNS Disorders • Orthopedics • Osteoporosis

Anti-osteoporotic Pharmacotherapy and Muscle Outcomes in Osteosarcopenia: a Source-Verified Translational Evidence Map. (PubMed, Calcif Tissue Int) - "Denosumab has the most coherent translational rationale through RANKL/RANK/NF-kB signaling, but randomized long-term-care data were neutral for muscle mass, strength, and performance despite bone mineral density improvement...Early pamidronate data in severe pediatric burns support prevention of resorption-linked muscle catabolism rather than reversal of established age-related sarcopenia. Bisphosphonates and teriparatide have preclinical or secondary signals; romosozumab and abaloparatide lack direct clinical muscle-efficacy evidence. Nandrolone is retained only as a historical positive control. Future trials should distinguish prevention from reversal and use factorial or rigorously standardized exercise designs with prespecified strength, muscle-mass, physical-performance, and pathway endpoints."

Journal • Review • Pediatrics • Sarcopenia • Thermal Injury

Repeated romosozumab with short-term ibandronate sequencing in high-risk osteoporosis: a retrospective single-center cohort study. (PubMed, JBMR Plus) - "All patients received eldecalcitol 0.75 μg daily. Repeated courses were accompanied by longitudinal improvements in recorded skeletal measures and bone turnover markers. Because this was an uncontrolled retrospective study and patient-level baseline data for the 19 patients who discontinued were unavailable in the analytical dataset, the findings should be considered descriptive and hypothesis-generating."

Journal • Retrospective data • Cardiovascular • Endocrine Disorders • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Is teriparatide linked to osteosarcoma? A disproportionality analysis of the FAERS database. (PubMed, Pharmacol Rep) - "This study highlights a disproportionate signal between teriparatide use and osteosarcoma when compared to all other drugs but not compared to romosozumab. Based on this and considering that previous evidence did not support an increased risk, further research is warranted to better understand this association."

Journal • Oncology • Osteoporosis • Osteosarcoma • Rheumatology • Sarcoma • Solid Tumor

Efficacy of romosuzumab in preventing and treating periprosthetic bone loss after hip replacement (ChiCTR) - P=N/A | N=20 | Not yet recruiting | Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University

New trial • Orthopedics • Osteoporosis

Comparing the Extent to Which Romosozumab (AMG 785) is Made Available in the Body When Administered as a Single SC Injection or as 2 SC Injections (clinicaltrials.gov) - P1 | N=308 | Not yet recruiting | Sponsor: Amgen

New P1 trial

Effects of romosozumab on the peripheral and axial skeleton in postmenopausal women at high fracture risk: real-world evidence from DXA and HR-pQCT data. (PubMed, Osteoporos Int) - "After 12 months of ROMO treatment, aBMD increased significantly at the lumbar spine and total hip, while volumetric BMD, microarchitecture, and strength at the peripheral skeleton did not change or deteriorated."

HEOR • Journal • Real-world evidence • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Adynamic Bone Disease in Chronic Kidney Disease: From PTH Suppression-Driven Remodeling Phenotype to Osteoanabolic Therapy. (PubMed, Am J Nephrol) - "ABD in advanced CKD represents a PTH suppression-driven skeletal remodeling phenotype characterized by osteoblast, osteoclast, and osteocyte dysfunction together with disruption of osteoblast-osteoclast coupling. Suppression of Wnt/β-catenin signaling, elevated sclerostin expression, impaired mechanotransduction, skeletal resistance to PTH, and accumulation of uremic toxins collectively contribute to globally reduced remodeling activity and defective microdamage repair. In the context of markedly suppressed bone turnover, antiresorptive therapy is biologically unlikely to confer skeletal benefit and may exacerbate impairment of bone remodeling and renewal. By contrast, anabolic strategies aimed at restoring PTH1R-dependent bone formation and remodeling activation are mechanistically appropriate in CKD-associated ABD. Current evidence suggests that intermittent PTH analog therapy, particularly teriparatide, may improve bone formation markers, bone mineral density, and..."

Journal • Review • Cardiovascular • Chronic Kidney Disease • Inflammation • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • FGF23 • SOST

Preventing Hip (Proximal Femoral) Fractures: An Evidence-Based Review for Clinicians. (PubMed, J Clin Med) - "Among medications, bisphosphonates, denosumab, and romosozumab-based sequential strategies show the strongest evidence for reducing hip-fracture risk, while teriparatide and abaloparatide have important roles in very-high-risk patients despite less direct hip-fracture evidence. Fracture liaison services, orthogeriatric co-management, prompt treatment after fragility fracture, and sustained adherence support are essential to close persistent care gaps. Preventing hip fractures therefore requires an integrated, risk-stratified approach that combines skeletal protection, falls prevention, and reliable health-system delivery."

Journal • Review • Musculoskeletal Diseases • Orthopedics

Pharmacologic Adjuncts for Bone Stress Injuries in Athletes: A Narrative Review of Current Evidence and Clinical Practice. (PubMed, Clin Ther) - "There is currently insufficient evidence to recommend routine use of bisphosphonates or osteoanabolic agents as treatment for an uncomplicated acute BSI in an otherwise healthy athlete. Assessment and correction of nutritional, and metabolic abnormalities, together with load management and rehabilitation, remain the foundation of care. Off-label treatment adjuncts discussed should be considered in recurrent, high-risk or delayed-healing BSI, with shared decision-making focus. Prospective outcome collection is likely to be the most pragmatic way to advance available evidence."

Journal • Review • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

STRONG-HIP: Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD (clinicaltrials.gov) - P4 | N=216 | Not yet recruiting | Sponsor: Sahlgrenska University Hospital

New P4 trial • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology

Effects of Limited versus Standard Dose Romosozumab followed by Denosumab on Peripheral Bone Density and Microarchitecture: The LIDA-HRpQCT Extension study (ASBMR 2026) - No abstract available

Late-breaking abstract

Impact of Prior Treatment and Predictive Factors in Sequential Romosozumab-Denosumab Therapy for Severe Osteoporosis. (PubMed, Yonsei Med J) - "Baseline skeletal status, prior treatment history, and nutritional or metabolic status may influence the BMD response to sequential romosozumab-denosumab therapy. These findings may help inform more individualized treatment strategies in clinical practice."

Biomarker • Journal • Observational data • Retrospective data • Musculoskeletal Diseases • Orthopedics • Osteoporosis • Rheumatology